New CAR T-Cell therapy aims to outperform current treatment for aggressive lymphoma

NCT ID NCT07479797

Recruiting now Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 12, 2026 · Updated 5 times

Summary

This phase 3 trial tests whether a new CAR T-cell therapy, KITE-753, works better than the current standard, axicabtagene ciloleucel (axi-cel), for adults with large B-cell lymphoma that returned or didn't respond to first treatment. About 550 participants will receive one infusion of either therapy. The main goal is to see if more people achieve complete remission at 6 months with KITE-753.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KITE-753 (a type of CAR T-cell therapy)
What this could lead to: If KITE-753 works better than the current CAR T-cell therapy, it could offer a more effective treatment option for people with hard-to-treat large B-cell lymphoma.
What could go wrong: This is an early-phase trial comparing two similar treatments, so it's unclear if KITE-753 will be superior. CAR T-cell therapies can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

CHU de Québec, Hôpital de l'Enfant-Jésus
RECRUITING

Québec, G1R2J6, Canada
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
RECRUITING

Duarte, California, 91010, United States
City of Hope - Chicago
RECRUITING

Zion, Illinois, 60099, United States
City of Hope Arizona
RECRUITING

Goodyear, Arizona, 85338, United States
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Epworth Healthcare
RECRUITING

East Melbourne, Victoria, 3002, Australia
Henry-Joyce Cancer Clinic
RECRUITING

Nashville, Tennessee, 37203, United States
Jewish General Hospital
RECRUITING

Montreal, H3T 1E2, Canada
McGill University Health Centre
RECRUITING

Montreal, H4A 0B1, Canada
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta
RECRUITING

Newnan, Georgia, 30265, United States
St. David's South Austin Medical Center
RECRUITING

Austin, Texas, 78704, United States
Stanford University
RECRUITING

Stanford, California, 94305, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.